1399-49-1 Usage
Uses
Used in Pharmaceutical Industry:
[(1aS)-1a,1bα,2,5aα,6,6aβ-Hexahydro-6α-hydroxy-1a-[(cinnamoyloxy)methyl]oxireno[4,5]cyclopenta[1,2-c]pyran-2α-yl]β-D-glucopyranoside is used as a pharmaceutical agent for its potential therapeutic properties. [(1aS)-1a,1bα,2,5aα,6,6aβ-Hexahydro-6α-hydroxy-1a-[(cinnamoyloxy)methyl]oxireno[4,5]cyclopenta[1,2-c]pyran-2α-yl]β-D-glucopyranoside's complex structure and stereochemistry may contribute to its ability to interact with biological targets, making it a candidate for the development of new drugs with various applications in medicine.
Used in Cosmetic Industry:
In the cosmetic industry, [(1aS)-1a,1bα,2,5aα,6,6aβ-Hexahydro-6α-hydroxy-1a-[(cinnamoyloxy)methyl]oxireno[4,5]cyclopenta[1,2-c]pyran-2α-yl]β-D-glucopyranoside may be utilized as an active ingredient for its potential skin health benefits. [(1aS)-1a,1bα,2,5aα,6,6aβ-Hexahydro-6α-hydroxy-1a-[(cinnamoyloxy)methyl]oxireno[4,5]cyclopenta[1,2-c]pyran-2α-yl]β-D-glucopyranoside's unique structure could provide anti-aging, moisturizing, or protective effects when incorporated into skincare formulations.
Used in Research and Development:
[(1aS)-1a,1bα,2,5aα,6,6aβ-Hexahydro-6α-hydroxy-1a-[(cinnamoyloxy)methyl]oxireno[4,5]cyclopenta[1,2-c]pyran-2α-yl]β-D-glucopyranoside serves as a valuable compound in scientific research and development. Its complex structure and potential biological activities make it an interesting subject for studies aimed at understanding its mechanisms of action, as well as for the development of new methodologies and techniques in organic synthesis and medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1399-49-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,3,9 and 9 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1399-49:
(6*1)+(5*3)+(4*9)+(3*9)+(2*4)+(1*9)=101
101 % 10 = 1
So 1399-49-1 is a valid CAS Registry Number.
